BioNTech Results Presentation Deck
RiboMabs: Nucleoside-modified mRNA Encoding Variable Antibody Formats
for in vivo Translation
In vivo translation and systemic availability of active drug at
therapeutically relevant plasma concentrations
mRNA backbone designed for minimal immunogenicity
Encoded antibodies target tumor-associated antigens
Sustained in vivo production may result in prolonged serum half-life
●
●
Shared LNP formulation across platform candidates
Liver-targeting LNP formulation for intravenous delivery
Encouraging preclinical data ¹
●
nature
medicine
Elimination of large tumors
in mice by mRNA-encoded
bispecific antibodies
Christiane R Stadler', Hayat Bähr-Mahmud¹, Leyla Celik',
Bernhard Hebich¹5, Alexandra S Roth¹5, René P Roth ¹,5,
Katalin Karikó¹, Özlem Türeci² & Ugur Sahin¹,3,4
Median tumor volume (mm)
1,500-
1,000-
500-
0
10 20 30 40 50
Days after tumor inoculation
CD3 x CLDN6 mRNA
rCD3 x CLDN6 protein
Luc mRNA
Vehicle control
Antibody-encoding mRNA
(drug substance)
5 UTR
CDS 1
CDS 2
Ommy+
BNT141
3 UTR
Product Candidate
BNT142
IgG, immunoglobulin G; LNP, lipid nanoparticles; TAA; CLDN18.2, Claudin-18.2; CD3 cluster of differentiation 3 (protein complex); CLDN, Claudin
1 Stadler, C.R. et al. Nature Medicine 2017 https://www.nature.com/articles/nm.4356
19
m14
Lipids
PEG-lipid
Helper lipid
Cationic lipid
Indication
(Targets)
Solid Tumors
(CLDN 18.2)
Solid Tumors
(CD3+CLDN6)
mRNA/LNP
(drug product)
60-120 nm
Antibody-
encoding
mRNA
In vivo
translation
to drug
Pre-clinical Phase 1
IgG
(1) Intravenous injection
(2) LNP target site: liver
(3) Translation and systemic availability of active drug
Phase 2
BIONTECHView entire presentation